Vitiligo - 白斑
指の白斑は、他の部位よりも治療が困難です。白斑症は美容的に見たくない他にすべて正常で、伝染しません。皮膚科では、光線治療またはレーザー治療（excimer）を週に2〜3回ずつ少なくとも1年以上治療するのが最も効果的な治療法です。財政的な理由や忙しくて病院に頻繁に行けない場合は、家庭用に許可された光線治療器を試してみることができます。
まぶたの白斑
手持ちの白斑
References
白斑は、メラノサイトの喪失により白い皮膚の斑点が生じる一般的な皮膚疾患です。最近の研究では、それが自己免疫疾患であることが示されています。見た目の問題として見られることが多いですが、精神的な健康や日常生活に深く影響を与える可能性があります。 2011 年、専門家は segmental vitiligo と呼ばれるタイプを他のタイプとは別に分類しました。
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
活動性白斑患者には、全身性糖質コルチコイド、光線療法、全身性免疫抑制剤など、いくつかの治療選択肢があります。安定した白斑患者は、局所コルチコステロイド、局所カルシニューリン阻害剤、光線療法、および移植処置によって症状が軽減される可能性があります。白斑の根本的なプロセスの理解における最近の進歩は、標的療法の開発につながりました。現在、JAK 阻害剤が最も有望であり、他の免疫抑制剤に共通する潜在的な感染症や全身性の副作用を活性化するリスクがあるにもかかわらず、良好な忍容性と機能的結果をもたらします。現在進行中の研究は、白斑の発症に関与する重要なサイトカインを特定することを目的としています (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) 。これらのサイトカインをブロックすることは、動物モデルや一部の患者において有望であることが示されています。さらに、 miRNA-based therapeutics と adoptive Treg cell therapy についての調査が進行中です。
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
白斑の治療法は知られていません。肌の色が薄い人には、通常、日焼け止めと化粧だけが推奨されます。他の治療オプションには、ステロイドクリームや光線療法が含まれる場合があります。
○ 処理
#Phototherapy
#Excimer laser
#Tacrolimus ointment